Registrace
- Registrace na stránkách Imedex
- Registrace do 11.6. 2009
Program konference
Friday, June 19, 2009
9:00 am Welcome and introduction William J. Gradishar, MD, FACP and Hope Rugo, MD
9:10 am Debate: Should MRI be performed prior to surgery on everyone with a diagnosis of early stage breast cancer?
9:40 am Debate: Should patients with low-risk node-positive disease have gene profiling performed to help with decision making?
10:10 am Debate: Should the SLN procedure be performed before or after administration of neoadjuvant chemotherapy?
10:40 am Discussion
10:50 am Break
11:10 am Optimal strategies for the treatment of metastatic triple-negative breast cancer
11:40 am Clinical applicability of available genomic profiling techniques
12:10 pm Debate: Should all patients receiving tamoxifen have CYP2D6 genotyping performed?
12:40 pm Discussion
12:50 pm Lunch
1:50 pm Debate: All patients with untreated metastatic ER+/HER2+ breast cancer should receive an anti-HER2 agent in addition to hormone therapy?
2:20 pm Debate: 68 year old with Stage II, ER +, lymph node (+) breast cancer with recent history of osteoporotic spine fractures now on calcium, Vitamin D, and a bisphosphonate. What adjuvant hormone therapy is most appropriate?
2:50 pm Debate: A 42-year old patient with triple-negative breast cancer receives neoadjuvant anthracycline/taxane-based chemotherapy, but significant residual disease remains after therapy. Should more systemic chemotherapy be administered?
3:20 pm Discussion
3:30 pm Adjourn
9:00 am Welcome and introduction William J. Gradishar, MD, FACP and Hope Rugo, MD
9:10 am Debate: Should MRI be performed prior to surgery on everyone with a diagnosis of early stage breast cancer?
9:40 am Debate: Should patients with low-risk node-positive disease have gene profiling performed to help with decision making?
10:10 am Debate: Should the SLN procedure be performed before or after administration of neoadjuvant chemotherapy?
10:40 am Discussion
10:50 am Break
11:10 am Optimal strategies for the treatment of metastatic triple-negative breast cancer
11:40 am Clinical applicability of available genomic profiling techniques
12:10 pm Debate: Should all patients receiving tamoxifen have CYP2D6 genotyping performed?
12:40 pm Discussion
12:50 pm Lunch
1:50 pm Debate: All patients with untreated metastatic ER+/HER2+ breast cancer should receive an anti-HER2 agent in addition to hormone therapy?
2:20 pm Debate: 68 year old with Stage II, ER +, lymph node (+) breast cancer with recent history of osteoporotic spine fractures now on calcium, Vitamin D, and a bisphosphonate. What adjuvant hormone therapy is most appropriate?
2:50 pm Debate: A 42-year old patient with triple-negative breast cancer receives neoadjuvant anthracycline/taxane-based chemotherapy, but significant residual disease remains after therapy. Should more systemic chemotherapy be administered?
3:20 pm Discussion
3:30 pm Adjourn
Saturday, June 20, 2009
9:00 am Welcome and introduction William J. Gradishar, MD, FACP and Hope Rugo, MD
9:10 am Debate: All patients with small T1a, T1b HER2-positive (ER-/PR-) disease should receive anti-HER2 therapy in adjuvant setting?
9:40 am Clinical updates in translational science for breast cancer: What’s on the horizon?
10:10 am Debate: Is short course radiotherapy as safe and effective as conventional fractionation schedules?
10:40 am Discussion
10:50 am Break
11:10 am Debate: Should tumor markers be utilized in the routine follow-up of patients with breast cancer?
11:40 am Cognitive impairment in the breast cancer patient: Fact or fiction? Hope Rugo, MD
12:00 pm Debate: Should anthracyclines be omitted from adjuvant chemotherapy regimens for patients with HER2-negative invasive breast cancer?
12:30 pm Discussion
12:40 pm Lunch
1:40 pm Management of brain metastases in ER+ and ER- breast cancer
2:10 pm Novel targeted therapies in clinical trials
2:40 pm Debate: What is the optimal management strategy of patients whose disease progresses while on trastuzumab?
3:10 pm Discussion
3:20 pm Adjourn
9:00 am Welcome and introduction William J. Gradishar, MD, FACP and Hope Rugo, MD
9:10 am Debate: All patients with small T1a, T1b HER2-positive (ER-/PR-) disease should receive anti-HER2 therapy in adjuvant setting?
9:40 am Clinical updates in translational science for breast cancer: What’s on the horizon?
10:10 am Debate: Is short course radiotherapy as safe and effective as conventional fractionation schedules?
10:40 am Discussion
10:50 am Break
11:10 am Debate: Should tumor markers be utilized in the routine follow-up of patients with breast cancer?
11:40 am Cognitive impairment in the breast cancer patient: Fact or fiction? Hope Rugo, MD
12:00 pm Debate: Should anthracyclines be omitted from adjuvant chemotherapy regimens for patients with HER2-negative invasive breast cancer?
12:30 pm Discussion
12:40 pm Lunch
1:40 pm Management of brain metastases in ER+ and ER- breast cancer
2:10 pm Novel targeted therapies in clinical trials
2:40 pm Debate: What is the optimal management strategy of patients whose disease progresses while on trastuzumab?
3:10 pm Discussion
3:20 pm Adjourn
Kontakt: meetings@imedex.com
Web: http://www.imedex....ements/a048-01.asp
- Přidat do kalendáře: 2009-06-19 00:00:00 2009-06-20 23:59:59 Europe/Prague Great Debates and Updates in Breast Cancer Palace Hotel, San Francisco, California, USA
